Group 1: BRP Inc. (DOO) - BRP Inc. is a powersports vehicles and marine products company with a Zacks Rank 1 [1] - The Zacks Consensus Estimate for its current year earnings increased by 5.5% over the last 60 days [1] - BRP's shares gained 9% over the last six months, while the S&P 500 declined by 4.8% [1] - The company has a Momentum Score of A [1] Group 2: Guardian Pharmacy Services, Inc. (GRDN) - Guardian Pharmacy Services is a pharmacy service company with a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings increased by 10.6% over the last 60 days [2] - Guardian Pharmacy's shares gained 13.5% over the last three months, compared to a 7% decline in the S&P 500 [2] - The company possesses a Momentum Score of A [2] Group 3: Permian Resources Corporation (PR) - Permian Resources Corporation is an oil and natural gas company with a Zacks Rank 1 [3] - The Zacks Consensus Estimate for its current year earnings increased by 53.1% over the last 60 days [3] - Permian Resources' shares gained 54.3% over the past three months, while the S&P 500 declined by 7% [3] - The company has a Momentum Score of A [3]

Group 1 - National Energy Services Reunited Corp. (NESR) has seen a 6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Blue Bird Corporation (BLBD) has experienced an 8.3% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Permian Resources Corporation (PR) has seen a significant 53.1% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Guardian Pharmacy Services, Inc. (GRDN) has had a 10.6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Lifetime Brands, Inc. (LCUT) has experienced a 35.6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3]

Core Viewpoint - Guardian Pharmacy Services, Inc. has announced the pricing of an upsized underwritten public offering of 6,000,000 shares of Class A common stock at a price of $31.00 per share, with the offering expected to close on March 20, 2026, subject to customary closing conditions [1][2]. Offering Details - The offering consists of 4,980,000 shares sold by certain selling stockholders and 1,020,000 shares issued by Guardian as part of a non-dilutive "synthetic secondary" transaction [1][2]. - The selling stockholders have granted underwriters a 30-day option to purchase up to an additional 900,000 shares at the public offering price, less the underwriting discount [1]. - Guardian intends to use all net proceeds from the offering to repurchase 1,020,000 shares from certain stockholders, ensuring that the total number of outstanding shares remains unchanged [2]. Company Overview - Guardian Pharmacy Services is a leading long-term care pharmacy services company that provides technology-enabled services to help residents of long-term health care facilities adhere to their drug regimens, thereby reducing care costs and improving clinical outcomes [7]. - As of December 31, 2025, Guardian operated 61 pharmacies, serving approximately 205,000 residents across about 8,400 long-term care facilities in 38 states [7].

Guardian Pharmacy Services (NYSE:GRDN) FY Conference Summary Company Overview - **Company**: Guardian Pharmacy Services - **Industry**: Healthcare Services, specifically focused on pharmacy services for assisted living facilities Key Points Business Performance and Momentum - Strong momentum exiting Q4 2025, primarily driven by vaccine clinics and acquisitions in the Pacific Northwest [2][3] - Successful management of vaccine clinics post-COVID, optimizing purchasing, reimbursement, and labor [2] - Acquisitions have leveraged synergies in national accounts, purchasing platforms, and revenue cycle management [3] Guidance and Future Outlook - Early guidance raised due to confidence in overcoming IRA headwinds, with strong vaccine clinic performance anticipated to continue into Q4 2026 [4] - Potential upside factors include increased acuity and better-than-expected performance from M&A and startups [5] Impact of IRA (Inflation Reduction Act) - Revenue impact from IRA projected to decrease from approximately $150 million in 2026 to $60-65 million in 2027, with further reductions in 2028 [8] - Company aims to mitigate EBITDA impact and return to normal metrics as the business stabilizes [8] M&A Strategy - M&A pipeline remains robust, with a focus on attractive geographies and operators willing to collaborate with Guardian [16][17] - Both M&A and contiguous startups are pursued concurrently to scale the business [18][19] - Recent acquisitions in Seattle and Oregon are performing ahead of schedule due to strong team capabilities and national account interest [21] Industry Trends and Demographics - Significant demographic trends with the aging population, particularly the baby boomer cohort turning 80, expected to drive demand in assisted living [26] - Anticipation of new building developments as occupancy rates approach levels that necessitate expansion [27] Innovative Programs and Technology - Early-stage pilot programs like falls risk prevention show promising results, utilizing clinical expertise and data analytics [30] - Guardian Shield program tracks clinical interventions and ensures medication regimens align with payors' formularies, resulting in cost savings for residents [31][32] - AI is being leveraged to enhance operational efficiency and improve service delivery [33] Financial Health and Capital Deployment - Strong cash conversion ratio of approximately 60%, with no debt on the balance sheet [36] - Future capital deployment strategies include continued M&A, strategic opportunities, and potential share buybacks [36][37] Regulatory Environment - Ongoing focus on drug pricing regulations, with efforts to align reimbursement algorithms with dispensing rates [39] - Participation in the Omnicare bankruptcy process presents potential opportunities for Guardian [40] Conclusion - Guardian Pharmacy Services is positioned for growth with a strong operational foundation, strategic M&A activities, and a favorable demographic trend in the assisted living sector. The company is actively managing regulatory challenges while innovating through technology and clinical programs to enhance service delivery and operational efficiency.

Core Insights - The company achieved organic revenue growth of 13%, driven by new resident additions, increased script volumes, and a shift toward higher-acuity care [1] - Adjusted EBITDA margins expanded by 50 basis points despite the costs associated with becoming a public company and integrating early-stage acquisitions [1] - The company effectively managed challenges in the branded inhaler category due to the American Rescue Plan through disciplined operational execution [1] Clinical and Operational Highlights - Clinical value was demonstrated through over 100,000 interventions and an insurance optimization program that saved residents approximately $56 million [1] - Management credits its competitive advantage to a local service model that alleviates labor burdens for facility operators facing an aging population [1] - Strategic investments in 'Guardian Hub' and 'Guardian Note' messaging systems have enhanced real-time visibility and workflow efficiency for facility partners [1] Financial Strategy - The company maintains a disciplined capital allocation strategy, leveraging strong cash flow to fund four acquisitions and multiple greenfield startups without the need for external financing [1]

Core Insights - Guardian Pharmacy Services reported strong financial performance for 2025, with adjusted EBITDA increasing by 27% year over year and margins expanding to 7.9% despite challenges from acquisitions and market conditions [1][5][10] - The company achieved organic revenue growth of 13%, attributed to new resident additions and increased script volumes, with total reported revenue growth of 18% for the year [2][5] - Management raised the 2026 adjusted EBITDA guidance to $120–$124 million while maintaining revenue guidance of $1.40–$1.42 billion, anticipating to offset pricing impacts from the Inflation Reduction Act [3][5][15] Financial Performance - Adjusted EBITDA for 2025 was reported at $115 million, with a significant increase in Q4 adjusted EBITDA by 53% to $39.5 million [5][10] - The company’s cash balance rose to approximately $66 million, up from $36 million at the end of Q3 2025, indicating strong cash flow generation [11] - Gross profit for Q4 increased by 27% to $85.5 million, with gross margin expanding to 21.5% from 19.8% a year earlier [6][10] Operational Highlights - Guardian served over 205,000 residents, marking a 10% increase year over year, with Q4 script volumes growing by 14% [4][6] - The company completed four acquisitions and continued investments in greenfield startups, funded by strong cash flow [4][11][12] - Vaccine clinics administered over 120,000 vaccines in Q3 and Q4, contributing to improved profitability and operational metrics [7][10] Strategic Outlook - Management noted the operational complexity due to the implementation of the Inflation Reduction Act and its potential impact on pricing and reimbursement dynamics [13][14] - The company is actively monitoring industry conditions, including facility-level consolidation and demographic trends, to identify market opportunities [14] - Future revenue impacts from additional branded drug negotiations under the IRA are expected to be smaller than those anticipated for 2026, with an estimated $65 million revenue headwind in 2027 [17]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported revenue of $397.6 million, a 17% year-over-year increase, with organic growth of 12% [15] - Adjusted EBITDA grew 53% year-over-year to $39.5 million, with margins expanding to 9.9% [18] - Full-year adjusted EBITDA for 2025 was $115 million, exceeding guidance [20] Business Line Data and Key Metrics Changes - The company served over 205,000 residents, a 10% increase year-over-year, with script volume growing 14% [15] - Vaccine script volumes increased by 3% year-over-year, contributing to improved profitability due to better purchasing and reimbursement [16] - Adjusted SG&A was 13% of revenue, down from 13.7% in the previous year, reflecting increased scale efficiencies [17] Market Data and Key Metrics Changes - The company anticipates continued pressure in the long-term care pharmacy ecosystem due to the IRA, but believes its scale and local service model will provide stability [10] - The demographic shift, with the first cohort of the "silver tsunami" entering their 80s, is expected to create a tailwind for the company [10] Company Strategy and Development Direction - The company plans to continue investing in acquisitions and greenfield startups while enhancing data analytics capabilities [6] - The focus remains on supporting partners with consistent, reliable execution amid industry changes [11] - The company is raising its 2026 adjusted EBITDA guidance to $120 million-$124 million, reflecting confidence in continued growth momentum [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in offsetting anticipated EBITDA impacts from the IRA in 2026 [9] - The company is closely monitoring operational complexities introduced by the IRA and aims to avoid disruptions to service levels and cash flow [10] - Management highlighted the importance of maintaining service continuity amid industry consolidation and operational changes [48] Other Important Information - The company increased its cash balance by approximately $60 million, reflecting strong cash generation [6] - Full-year return on equity was 27%, underscoring a disciplined approach to capital allocation [7] Q&A Session Summary Question: Can you help us understand what's durable, what's vaccine, and what's non-recurring in the quarter? - Management indicated that the run rate for adjusted EBITDA is approximately $110 million, with certain positive variabilities not projected to continue [25] Question: Did the vaccine program contribute more this year than last year? - Management confirmed that the vaccine program continued to be significant in Q4, with improved reimbursement contributing to profitability [27] Question: What were you able to get done from a contracting standpoint to better balance profit streams? - Management noted progress in aligning gross margin dollars with the high percentage of generic prescriptions dispensed [29] Question: Is the gap between potential margin and realized margin still what it was a couple of quarters ago? - Management reported that the gap has increased to approximately 90 basis points, reflecting ongoing investments for future profitability [30] Question: Can you discuss the opportunity around share gain with struggling competitors? - Management acknowledged potential opportunities arising from industry disruptions, including bankruptcy filings among competitors [41] Question: Are you seeing efficiencies and improvements in labor inflation? - Management indicated that efficiencies are primarily driven by scaling the existing labor force rather than improvements in labor inflation [42] Question: How do you ensure continuity of service amid operational changes? - Management emphasized that industry consolidation provides opportunities to maintain service and meet new operating groups [48]

Core Viewpoint - Guardian Pharmacy Services, Inc. is actively participating in key industry conferences to enhance visibility and communicate its growth trajectory and financial outlook for 2026 [1]. Group 1: Conference Participation - Guardian Pharmacy Services will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16, 2026, featuring a fireside chat with the CEO and CFO [1]. - The company will also present at the Raymond James Institutional Investors Conference in Orlando, Florida, on March 2, 2026 [1]. Group 2: Financial Performance and Outlook - Guardian Pharmacy Services is set to release its fourth quarter and full-year 2025 financial results on March 11, 2026, followed by a conference call to discuss these results [1]. - The company is reiterating its 2025 guidance and providing a preliminary financial outlook for 2026, expecting low double-digit adjusted EBITDA growth supported by its operating model and anticipated drug pricing changes [1].

Company Overview - CareRx Corporation is Canada's leading provider of pharmacy services to seniors living and other congregate care communities, including long-term care homes, retirement homes, assisted living facilities, and group homes [2] - The company operates a national network of pharmacy fulfillment centers strategically located across Canada, enabling timely and cost-effective medication delivery [2] - CareRx utilizes advanced technology to automate the preparation and verification of multi-dose compliance packaging, ensuring high safety and adherence for individuals with complex medication regimens [2] Dividend Announcement - The Board of Directors of CareRx has declared a dividend of CAD$0.02 per outstanding common share, payable on April 9, 2026, to shareholders of record as of March 19, 2026 [1] - This dividend is classified as an "eligible dividend" for Canadian income tax purposes, with specific tax implications for non-residents and U.S. residents [1]

Core Insights - CareRx Corporation reported strong financial results for the fourth quarter and full year ended December 31, 2025, highlighting significant year-over-year growth in Adjusted EBITDA and improved EBITDA margins [2][3][9] Financial Performance - Revenue for the year reached CAD 370.2 million, a slight increase from CAD 366.7 million in 2024, while fourth-quarter revenue was CAD 96.1 million, up from CAD 92.2 million in Q4 2024 [3][9] - Adjusted EBITDA for the year was CAD 32.9 million, compared to CAD 30.3 million in 2024, and for Q4 2025, it was CAD 8.8 million, up from CAD 7.6 million in Q4 2024 [3][9] - Adjusted EBITDA margin improved to 8.9% for the year and 9.2% for Q4 2025, compared to 8.3% and 8.2% in the respective prior periods [3][9] - Net income for the year was CAD 26.1 million, a significant recovery from a loss of CAD 4.5 million in 2024, with Q4 net income at CAD 23.8 million compared to a loss of CAD 2.2 million in Q4 2024 [3][9] - Cash provided by operations was CAD 9.6 million for Q4 2025, compared to CAD 8.4 million in Q4 2024 [3][9] Operational Highlights - Average beds serviced increased to 92,250 in Q4 2025, up from 87,658 in Q4 2024, reflecting the company's expansion efforts [9] - The company expanded its platform by adding over 4,500 additional beds during the year [2][9] - Net Debt decreased to CAD 27.1 million, down from CAD 35.8 million in 2024, indicating improved financial leverage [10][16] Dividend Announcement - The Board of Directors declared a dividend of CAD 0.02 per common share, payable on April 9, 2026, to shareholders of record as of March 19, 2026 [4]